The Kidney Disease Outcomes Quality Initiative recommends discussing kidney replacement therapy options when patients reach chronic kidney disease (CKD) stage 4 or have an estimated GFR <30 mL/min per 1.73 m2 (1). Preparing patients and vetting the options for renal replacement therapy remain pivotal to providing excellent CKD care, which ultimately leads to better patient outcomes. During these conversations, it is crucial that patients fully examine the quality of life, morbidity, and mortality associated with each therapy. For years, researchers have dedicated their time to examining the effects of these modalities in hopes of better facilitating these discussions. With the 2019 executive order on Advancing American Kidney Health, the number of patients choosing home dialysis therapies is likely to increase in the upcoming years. Given this, we believe it is imperative for all clinicians to review and be well versed in the literature on the quality of life, morbidity, and mortality of peritoneal dialysis (PD) before initiating therapy.
United States Renal Data System. 2019 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2019. https://www.usrds.org/media/2371/2019-executive-summary.pdf